PIRTOBRUTINIB MONOTHERAPY IN BRUTON TYROSINE KINASE INHIBITOR-INTOLERANT PATIENTS WITH B-CELL MALIGNANCIES: RESULTS OF THE PHASE I/II BRUIN TRIAL

Pirtobrutinib monotherapy in Bruton tyrosine kinase inhibitor-intolerant patients with B-cell malignancies: results of the phase I/II BRUIN trial

Bruton tyrosine kinase inhibitors (BTKi) have transformed the treatment of B-cell malignancies, but intolerance has often led to their discontinuation.The phase 1/2 BRUIN study evaluated pirtobrutinib, a highly selective non-covalent (reversible) BTKi, in patients with R/R B-cell malignancies Throat Support (NCT03740529).Pirtobrutinib was investiga

read more

Supra- and infra-tentorial subacute extradural hematoma

Extradural hematoma (EDH) is a rare but serious Isolator complication of brain injury.The supra- and infra-tentorial EDH is even rarer and only a few articles focusing on this topic have been published.The clinical manifestations are nonspecific but early diagnosis of supra- and infra-tentorial EDH and prompt treatment are mandatory to avoid compli

read more



Mantle cell lymphoma: involvement of nodal and extranodal sites in the head and neck, with multifocal oral lesions

Mantle cell lymphoma (MCL) is a malignant B-cell Concealers neoplasm, which comprises monomorphic and small- to medium-sized mantle zone-derived lymphoid cells.It is characterized by chromosomal translocation t(11;14)(q13;q32) and CCND1 truncation, resulting in cell cycle deregulation.It is an aggressive type of non-Hodgkin lymphoma with a propensi

read more